The Icahn School of Medicine at Mount Sinai (ISMMS) was awarded a $237,023 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) with a period of performance from March 1, 2025 to February 29, 2028. The grant supports the development of a scalable, high-throughput single-cell multi-omic profiling method (SHARE-ME-SEQ) that can jointly capture gene expression, chromatin accessibility, and DNA methylation in large numbers of cells. This technology will be applied to study the interplay between DNA methylation, chromatin state, and gene regulation in healthy hematopoietic cells and cells from acute myeloid leukemia (AML) patients with specific genetic mutations. The goal is to gain unprecedented insights into the epigenetic mechanisms underlying AML initiation and progression, potentially identifying new therapeutic targets. This research aligns with the Cancer Biology Research program's objectives of supporting fundamental investigations into the molecular and cellular basis of cancer.